News

News 30.01.2020 Schlieren (Zurich), Switzerland, January 30, 2020 – Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone, Vitoss® BA2X (Stryker Corp.) and Novabone Putty® (Novabone Products, LLC) in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study...

Internal events
Event date: 25.02.2020 WHEN: 25 February 2020 09:00 - 12:00 WHERE: Bio-Technopark Auditorium, Wagistrasse 25, Schlieren-Zurich In preparation for the second Redefining Early Stage Investments (RESI) conference to be held in Europe, Life Science Nation and Venture Valuation are offering Tech Hubs around Europe a Bootcamp addressing key topics for early-stage life science companies. Program and...

Internal events
Event date: 26.03.2020 During a 30 minutes IP coaching from Dr. Peter Steinecke, German and European Patent Attorney from WJS , you will have the opportunity to discuss challenges to turn your innovation to a patentable invention and establish Intellectual Property (IP) for your company. In addition, you may ask for advice how...

Internal events
Event date: 04.02.2020 Bio-Technopark Schlieren-Zürich and Euronext are delighted to invite you to a discussion on different financing perspectives and opportunities, followed by a podium discussion taking place on Tuesday 4 February 2020 from 16:00 to 18:00, Auditorium Wagistrasse 25. More information and registration    

News 10.01.2020 Zurich-Schlieren, Switzerland, January 10, 2020. Proteomedix, a swiss diagnostics company committed to advance prostate cancer care announced today that its board of directors has appointed Helge Lubenow as Chief Executive Officer effective January 1, 2020. Helge will succeed Ralph Schiess, co-founder of Proteomedix who is transitioning to a newly established...